Other

Investment in biotechnology companies that are determined to be unconsolidated variable interest entities

Biogen Investment in biotechnology companies that are determined to be unconsolidated variable interest entities decreased by 2.8% to $48.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 150.8%, from $19.30M to $48.40M. Over 5 years (FY 2020 to FY 2025), Investment in biotechnology companies that are determined to be unconsolidated variable interest entities shows an upward trend with a 31.2% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2015
Last reportedQ1 2026
Metric ID: other_investment_in_biotechnology_companies_that_are_det_ee86a4

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$15.20M$17.20M$24.60M$24.10M$23.50M$25.30M$27.80M$28.00M$25.20M$24.40M$16.40M$23.80M$22.80M$23.60M$23.60M$19.30M$49.30M$44.80M$49.80M$48.40M
QoQ Change+13.2%+43.0%-2.0%-2.5%+7.7%+9.9%+0.7%-10.0%-3.2%-32.8%+45.1%-4.2%+3.5%+0.0%-18.2%+155.4%-9.1%+11.2%-2.8%
YoY Change+54.6%+47.1%+13.0%+16.2%+7.2%-3.6%-41.0%-15.0%-9.5%-3.3%+43.9%-18.9%+116.2%+89.8%+111.0%+150.8%
Range$15.20M$49.80M
CAGR+27.6%
Avg YoY Growth+34.9%
Median YoY Growth+14.6%

Frequently Asked Questions

What is Biogen's investment in biotechnology companies that are determined to be unconsolidated variable interest entities?
Biogen (BIIB) reported investment in biotechnology companies that are determined to be unconsolidated variable interest entities of $48.40M in Q1 2026.
How has Biogen's investment in biotechnology companies that are determined to be unconsolidated variable interest entities changed year-over-year?
Biogen's investment in biotechnology companies that are determined to be unconsolidated variable interest entities increased by 150.8% year-over-year, from $19.30M to $48.40M.
What is the long-term trend for Biogen's investment in biotechnology companies that are determined to be unconsolidated variable interest entities?
Over 5 years (2020 to 2025), Biogen's investment in biotechnology companies that are determined to be unconsolidated variable interest entities has grown at a 31.2% compound annual growth rate (CAGR), from $12.80M to $49.80M.